PE20040324A1 - Formulaciones liquidas de baja dosis de entecavir y uso - Google Patents
Formulaciones liquidas de baja dosis de entecavir y usoInfo
- Publication number
- PE20040324A1 PE20040324A1 PE2003000351A PE2003000351A PE20040324A1 PE 20040324 A1 PE20040324 A1 PE 20040324A1 PE 2003000351 A PE2003000351 A PE 2003000351A PE 2003000351 A PE2003000351 A PE 2003000351A PE 20040324 A1 PE20040324 A1 PE 20040324A1
- Authority
- PE
- Peru
- Prior art keywords
- entecavir
- liquid
- formulated
- composition
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A COMPOSICIONES FARMACEUTICAS LIQUIDAS QUE TIENEN UNA BAJA DOSIS DE ENTECAVIR PARA TRATAR INFECCIONES POR EL VIRUS DE HEPATITIS B COMO: a) UNA COMPOSICION LIQUIDA DE ENTECAVIR LISTA PARA USAR, FORMULADA PARA SER ESTABLE Y DE SABOR AGRADABLE, DONDE EL ENTECAVIR ESTA PRESENTE EN LA COMPOSICION EN UNA CANTIDAD DE ALREDEDOR DE 0.001% HASTA ALREDEDOR DE 20% P/V, b) UNA COMPOSICION LIQUIDA QUE ESTA FORMULADA A PARTIR DE UN POLVO PARA CONSTITUCION COMO UNA COMPOSICION LIQUIDA EN ELMOMENTO DE USO, QUE COMPRENDE ALREDEDOR DE 0.001% HASTA ALREDEDOR DE 20% PESO DE ENTECAVIR BASADO EN EL PESO TOTAL DE LA COMPOSICION EN POLVO.ESTAS COMPOSICIONES TIENEN POR LO MENOS UN COMPONENTE ADICIONAL SELECCIONADO DE UNO O MAS DE LOS SIGUIENTES: EDULCORANTE, CONSERVADOR, AGENTE SABORIZANTE, AGENTE DE SOLUCION AMORTIGUADORA AGENTE DE AJUSTE DE PH O COMBINACION DE ESTOS, TAMBIEN PUEDEN SER FORMULADAS EN COMBINACION CON OTROS AGENTES FARMACEUTICAMENTE ACTIVOS COMO DIDANOSINA, LAMIVUDINA, ABACAVIR, ADEFOVIR, ADEFOVIR DIPIVOXIL,FAMCICLOVIR, PROTEINAS INMUNOMODULADORAS DE HEPATITIS B ENTRE OTROS.TAMBIEN SE REFIERE A UN PROCESO PARA FORMULAR AMBAS COMPOSICIONES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37067402P | 2002-04-08 | 2002-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20040324A1 true PE20040324A1 (es) | 2004-05-29 |
Family
ID=29250568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2003000351A PE20040324A1 (es) | 2002-04-08 | 2003-04-08 | Formulaciones liquidas de baja dosis de entecavir y uso |
Country Status (22)
Country | Link |
---|---|
US (1) | US20030190334A1 (es) |
EP (1) | EP1492510A4 (es) |
JP (1) | JP2005528389A (es) |
KR (1) | KR20040099403A (es) |
CN (1) | CN1319517C (es) |
AR (1) | AR039388A1 (es) |
AU (1) | AU2003226259A1 (es) |
BR (1) | BR0309057A (es) |
CA (1) | CA2481092A1 (es) |
EA (1) | EA008102B1 (es) |
EC (1) | ECSP045349A (es) |
HR (1) | HRP20040893A2 (es) |
MX (1) | MXPA04009735A (es) |
MY (1) | MY131488A (es) |
NO (1) | NO20044451L (es) |
NZ (1) | NZ535535A (es) |
PE (1) | PE20040324A1 (es) |
PL (1) | PL372322A1 (es) |
RS (1) | RS88404A (es) |
TW (1) | TWI275392B (es) |
WO (1) | WO2003086367A1 (es) |
ZA (1) | ZA200407672B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7511139B2 (en) | 2004-06-04 | 2009-03-31 | Bristol-Myers Squibb Company | Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation |
CN1732944B (zh) * | 2005-09-02 | 2013-05-08 | 海南中和药业有限公司 | 恩替卡韦分散片及其制备方法 |
US20070060599A1 (en) * | 2005-09-09 | 2007-03-15 | Dimarco John D | Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one |
RU2381807C1 (ru) * | 2008-07-18 | 2010-02-20 | Алексей Глебович Одинец | Противовирусное средство |
CN101869569A (zh) * | 2009-04-21 | 2010-10-27 | 李迪 | 即用型恩替卡韦组合物 |
EP2508172A1 (en) | 2011-04-06 | 2012-10-10 | Zentiva, a.s. | Stable and uniform formulations of entecavir and preparation method thereof |
PE20141328A1 (es) | 2011-08-16 | 2014-10-04 | Gilead Sciences Inc | Tenofovir alafenamida hemifumarato |
CN102908312B (zh) * | 2011-11-10 | 2014-06-04 | 陈小花 | 抗乙肝病毒液体组合物 |
US8517850B1 (en) * | 2012-12-11 | 2013-08-27 | Cobra Golf Incorporated | Golf club grip with device housing |
KR101462018B1 (ko) * | 2013-04-01 | 2014-11-19 | 썬시스템즈(주) | 엔테카비르 함유 구강 붕해형 필름제제 |
CN103301071A (zh) * | 2013-06-03 | 2013-09-18 | 北京阜康仁生物制药科技有限公司 | 一种稳定的恩替卡韦无糖型颗粒剂及其制备方法 |
CN105722503A (zh) * | 2013-08-06 | 2016-06-29 | 东国制药株式会社 | 恩替卡韦微球及包含其的非口服给药用药学组合物 |
EP3158998A4 (en) * | 2014-06-20 | 2018-02-14 | CTC Bio, Inc. | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor |
CN104083374A (zh) * | 2014-07-18 | 2014-10-08 | 石家庄创建医药科技有限公司 | 一种恩替卡韦口服液组合物 |
CN109984996B (zh) * | 2018-01-02 | 2022-01-18 | 扬子江药业集团有限公司 | 恩替卡韦口服溶液及其制备方法 |
CN108434096A (zh) * | 2018-06-20 | 2018-08-24 | 广州大光制药有限公司 | 一种恩替卡韦口服溶液及其制备方法 |
KR20210029787A (ko) * | 2018-06-29 | 2021-03-16 | 학교법인 도시샤 | 엠리카산을 포함하는 제제 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4489026A (en) * | 1982-09-07 | 1984-12-18 | The Upjohn Company | Process for preparing solid unit dosage forms of ultra-low dose drugs |
US5206244A (en) * | 1990-10-18 | 1993-04-27 | E. R. Squibb & Sons, Inc. | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
TW536403B (en) * | 1997-03-24 | 2003-06-11 | Glaxo Group Ltd | An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy |
US5997905A (en) * | 1998-09-04 | 1999-12-07 | Mcneil-Ppc | Preparation of pharmaceutically active particles |
JP2002534438A (ja) * | 1999-01-12 | 2002-10-15 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | 新規治療法 |
CZ303395B6 (cs) * | 2000-02-29 | 2012-08-29 | Bristol-Myers Squibb Co. | Farmaceutický prostredek s nízkou dávkou entekaviru |
CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
-
2003
- 2003-04-02 TW TW092107553A patent/TWI275392B/zh not_active IP Right Cessation
- 2003-04-02 MY MYPI20031228A patent/MY131488A/en unknown
- 2003-04-03 CA CA002481092A patent/CA2481092A1/en not_active Abandoned
- 2003-04-03 EP EP03746598A patent/EP1492510A4/en not_active Withdrawn
- 2003-04-03 RS YU88404A patent/RS88404A/sr unknown
- 2003-04-03 CN CNB038132877A patent/CN1319517C/zh not_active Expired - Fee Related
- 2003-04-03 JP JP2003583388A patent/JP2005528389A/ja active Pending
- 2003-04-03 MX MXPA04009735A patent/MXPA04009735A/es not_active Application Discontinuation
- 2003-04-03 PL PL03372322A patent/PL372322A1/xx unknown
- 2003-04-03 AU AU2003226259A patent/AU2003226259A1/en not_active Abandoned
- 2003-04-03 BR BR0309057-4A patent/BR0309057A/pt not_active IP Right Cessation
- 2003-04-03 WO PCT/US2003/010371 patent/WO2003086367A1/en active Application Filing
- 2003-04-03 EA EA200401298A patent/EA008102B1/ru not_active IP Right Cessation
- 2003-04-03 KR KR10-2004-7015936A patent/KR20040099403A/ko not_active Application Discontinuation
- 2003-04-03 NZ NZ535535A patent/NZ535535A/en unknown
- 2003-04-04 US US10/407,287 patent/US20030190334A1/en not_active Abandoned
- 2003-04-07 AR ARP030101211A patent/AR039388A1/es not_active Application Discontinuation
- 2003-04-08 PE PE2003000351A patent/PE20040324A1/es not_active Application Discontinuation
-
2004
- 2004-09-22 ZA ZA200407672A patent/ZA200407672B/en unknown
- 2004-09-29 HR HR20040893A patent/HRP20040893A2/hr not_active Application Discontinuation
- 2004-10-08 EC EC2004005349A patent/ECSP045349A/es unknown
- 2004-10-19 NO NO20044451A patent/NO20044451L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HRP20040893A2 (en) | 2005-02-28 |
CA2481092A1 (en) | 2003-10-23 |
JP2005528389A (ja) | 2005-09-22 |
EP1492510A1 (en) | 2005-01-05 |
CN1658844A (zh) | 2005-08-24 |
EP1492510A4 (en) | 2006-01-11 |
EA008102B1 (ru) | 2007-04-27 |
TWI275392B (en) | 2007-03-11 |
AU2003226259A1 (en) | 2003-10-27 |
ECSP045349A (es) | 2005-01-03 |
BR0309057A (pt) | 2005-02-01 |
US20030190334A1 (en) | 2003-10-09 |
WO2003086367A1 (en) | 2003-10-23 |
KR20040099403A (ko) | 2004-11-26 |
EA200401298A1 (ru) | 2005-02-24 |
AR039388A1 (es) | 2005-02-16 |
NO20044451L (no) | 2004-11-04 |
TW200306840A (en) | 2003-12-01 |
NZ535535A (en) | 2006-09-29 |
MY131488A (en) | 2007-08-30 |
MXPA04009735A (es) | 2005-01-11 |
RS88404A (en) | 2006-12-15 |
CN1319517C (zh) | 2007-06-06 |
PL372322A1 (en) | 2005-07-11 |
ZA200407672B (en) | 2005-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20040324A1 (es) | Formulaciones liquidas de baja dosis de entecavir y uso | |
ES2620413T3 (es) | Formulaciones veterinarias antihelmínticas tópicas | |
BRPI0412849A (pt) | compostos, composições e usos de análogos de nucleosìdeo de purina para o tratamento de flaviviridae, incluindo hepatite c | |
WO2006000922A3 (en) | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae | |
AR035711A1 (es) | Prodrogas 3' de 2'-desoxi-beta-l-nucleosidos; sus composiciones farmaceuticas; metodo para el tratamiento o profilaxis de una infeccion del virus de la hepatitis b y sus usos para la manufactura de composiciones farmaceuticas | |
BRPI0509708B8 (pt) | espuma farmacêutica, composição de espuma de pimecrolimus contendo glicol de hexileno, opcionalmente álcool de oleil, dimetilisosorbídeo e/ou triglicerídeos de cadeia média e uso | |
HUP0301405A2 (hu) | Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények | |
CA2366702A1 (en) | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents | |
BRPI0113042B8 (pt) | composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato | |
CY1112523T1 (el) | Υγρες συνθεσεις κανναβινοειδων για χορηγηση σε βλεννογονο | |
SV1995000002A (es) | Uso y obtencion de derivados tetraciclicos ref. 1233cv/vs | |
EA200100298A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5 | |
ECSP045496A (es) | "preparaciones acidas de insulina con estabilidad mejorada" | |
ATE294571T1 (de) | Echinocandin pharmazeutische zusammensetzungen | |
HUP9903732A2 (hu) | cGMP-szintjét növelő szerek alkalmazása a jóindulatú prosztatatúltengés kezelésére szolgáló gyógyszerkészítmények előállítására | |
AR044200A1 (es) | Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo | |
BRPI0418115A (pt) | formulação lìquida estável de hormÈnio de crescimento | |
ES2163631T3 (es) | Un peptido mejorado, composicion inmunogenica y vacuna o preparacion medica, un procedimiento para inmunizar a los animales contra la hormona lhrh, analogos del peptido lhrh repetidos en tandem y su uso como vacuna. | |
ES2732892T3 (es) | Composición de tratamiento de hongos en las uñas | |
CO5241355A1 (es) | Forma envasada de composiciones farmaceuticas nucleosidicas activas para vacunas contra la hepatitis | |
AR056017A1 (es) | Formulaciones de vacuna animal, metodo para preparar una formulacion de vacuna y componente estabilizador de vacuna | |
AU3548901A (en) | Veterinary compositions for the treatment of parasitic diseases | |
DE69006401D1 (de) | Aerosolzusammensetzungen zur topischen Anwendung. | |
BR0313175A (pt) | Formulações farmacêuticas compreendendo combinações de epinastina, pseudoefedrina e metilefedrina | |
WO2001045727A3 (en) | Stabilized veterinary compositions comprising more than one antiviral agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |